Entera Bio Ltd. (ENTX) Executes Key Regulatory Milestones for EB613 Jul 18, 2022 07:05AM
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position Jul 18, 2022 07:05AM
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy May 16, 2022 08:00AM
Entera Bio Appoints Two New External Independent Members to the Board of Directors Oct 2, 2018 08:00AM